Avexa Chairman Retires.MELBOURNE, Australia -- Avexa Ltd (AVX AVX Adult Video XXX AVX Avid Visual Extensions AVX anti Virus Expert ) announced today that its Chairman, Dr Hugh Niall, has retired from the Board of the Company effective immediately. Non-Executive Director A non-executive director (NED, also NXD) or outside director is a member of the board of directors of a company who does not form part of the executive management team. He or she is not an employee of the company or affiliated with it in any other way. Mr. Stephen Cooper Stephen Cooper is the name of:
Dr. Niall, 70, was appointed in September 2004. He said today, "I have greatly enjoyed working with my fellow Directors and the management of Avexa during an exciting and productive phase of the Company's development. I thank them for their unfailing support. I am reducing the number of my work commitments so that I can spend more time with my family." Mr. Cooper has been a director of Avexa since November 2005. He is a director of Grant Samuel, a leading independent Australian advisory firm and has wide ranging experience in mergers and acquisitions, corporate restructuring and capital raisings. Mr Cooper commented, "Dr Niall has made an outstanding contribution to Avexa's growth and we wish him well. Avexa is at an exciting point in its development, with the Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA trial for apricitabine now underway and growing momentum in Avexa's integrase and anti-bacterial programmes. I look forward to the continued progress of the Company." www.avexa.com.au Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of drugs for the treatment of infectious diseases. Avexa has dedicated resources and funding for key projects including its HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. integrase program and an antibiotic program for antibiotic-resistant bacterial infections. The Company's lead program is apricitabine (ATC ATC Air Traffic Control ATC Average Total Cost ATC Certified Athletic Trainer ATC At the Center (Hartford, Maine retreat center) ATC Applied Technology Council ATC All Things Considered ), an anti-HIV drug which has successfully completed the 48 week dosing of its Phase 2b trial and has recently initiated Phase 3 trials. Avexa has entered into a collaboration with TargetDrug in China to identify new CCR 1. CCR - condition code register. 2. CCR - (Database) concurrency control and recovery. 5 inhibitors for the treatment of HIV. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion